Jeffrey Sevigny

Jeff Sevigny is the Chief Medical Officer. With more than 15 years of clinical research experience, Jeff brings executive leadership and technical expertise across the development spectrum of multiple neurological diseases. Beyond drug development, Jeff has been integral in driving multiple business development agreements, active in multiple public-private partnerships, and was recently Chairman of the Alzheimer’s Association Research Roundtable. Jeff joined Prevail from F. Hoffmann-La Roche AG, where he was Vice President and Global Head of Translational Medicine Neuroscience, leading a group of physicians, clinical and biomarker scientists, and project team leaders. There, he oversaw the successful early development of the company’s HTT ASO program in Huntington’s disease and balovaptan in autism. Prior to Roche, he was Senior Director of Clinical Development at Biogen, where he led the development of the Company’s early and late-stage neurodegeneration portfolio. Before that, he held positions at Novartis AG and Merck & Co. Earlier in his career, Jeff held academic appointments as Assistant Professor of Neurology at Albert Einstein School of Medicine and Assistant Professor of Clinical Neurology at Columbia University College of Physicians and Surgeons.

Jeff holds an M.D. from Tufts University School of Medicine and an A.B. in biochemistry from Bowdoin College. He completed a neurology residency at the Neurological Institute of New York at Columbia University Medical Center and a fellowship in Aging & Dementia and Neuro-Epidemiology at Sergievsky Center at Columbia University and Columbia University Mailman School of Public Health.